Ignite Creation Date:
2024-05-06 @ 5:05 PM
Last Modification Date:
2024-10-26 @ 2:22 PM
Study NCT ID:
NCT05191004
Status:
WITHDRAWN
Last Update Posted:
2023-07-11
First Post:
2021-12-22
Brief Title:
Study of NUV-422 in Combination With Fulvestrant in Patients With HRHER2- aBC
Sponsor:
Nuvation Bio Inc
Organization:
Nuvation Bio Inc
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Breast Tumor |
| Advanced Breast Cancer |
| Metastatic Breast Cancer |
| Breast Cancer |
| Breast Carcinoma |
| Cancer of the Breast |
| Cancer of Breast |
| Malignant Tumor of Breast |
Keywords:
| Name | View |
|---|---|
| CDK246 | View |
| Phase 1 | View |
| Phase 2 | View |
| metastatic breast cancer | View |
| advanced breast cancer | View |
| hormone receptor positive | View |
| HR | View |
| human epidermal growth factor receptor 2 negative | View |
| HER2- | View |
| HR HER2- | View |
| estrogen receptor positive | View |
| ER | View |
| NUV-422 | View |
| fulvestrant | View |
| CDK | View |
| CDK inhibition | View |